Lyell Immunopharma Inc. (LYEL)
0.61
0.04 (6.18%)
At close: Jan 15, 2025, 12:44 PM
Income Statement (Annual)
Get detailed income statement breakdowns, uncovering revenue, expenses, and much more.
| Year | FY23 | FY22 | FY21 | FY20 | FY19 |
| Revenue | 130.00K | 84.68M | 10.65M | 7.76M | 657.00K |
| Cost of Revenue | n/a | 16.47M | 14.54M | 7.47M | n/a |
| Gross Profit | 130.00K | 68.22M | -3.88M | 281.00K | 657.00K |
| Operating Income | -247.01M | -183.12M | -214.78M | -211.94M | -102.09M |
| Interest Income | 23.45M | 7.05M | 1.17M | 5.94M | 8.12M |
| Pretax Income | -234.63M | -183.12M | -250.22M | -204.47M | -129.38M |
| Net Income | -234.63M | -4.75M | -285.50M | -198.53M | -121.26M |
| Selling & General & Admin | 66.98M | 117.31M | 89.06M | 46.88M | 39.15M |
| Research & Development | 182.94M | 159.19M | 138.69M | 182.24M | 63.59M |
| Other Expenses | -2.79M | 1.89M | -2.32M | -9.43M | -35.41M |
| Operating Expenses | 247.14M | 276.50M | 225.43M | 219.69M | 102.75M |
| Interest Expense | n/a | n/a | n/a | n/a | n/a |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | 247.14M | 276.50M | 225.43M | 219.69M | 102.75M |
| Income Tax | n/a | -178.36M | 35.28M | -5.94M | -8.12M |
| Shares Outstanding (Basic) | 250.98M | 247.08M | 242.74M | 246.58M | 246.58M |
| Shares Outstanding (Diluted) | 250.98M | 247.08M | 242.74M | 246.58M | 246.58M |
| EPS (Basic) | -0.93 | -0.02 | -1.18 | -0.81 | -0.49 |
| EPS (Diluted) | -0.93 | -0.02 | -1.18 | -0.81 | -0.49 |
| EBITDA | -226.76M | -166.65M | -199.94M | -207.64M | -100.83M |
| Depreciation & Amortization | 20.25M | 16.47M | 14.54M | 7.47M | 4.38M |